277.12
0.99 (0.36%)
| Penutupan Terdahulu | 276.13 |
| Buka | 277.00 |
| Jumlah Dagangan | 216,124 |
| Purata Dagangan (3B) | 245,561 |
| Modal Pasaran | 28,751,536,128 |
| Harga / Pendapatan (P/E TTM) | 62.70 |
| Harga / Pendapatan (P/E Ke hadapan) | 43.86 |
| Harga / Jualan (P/S) | 5.39 |
| Harga / Buku (P/B) | 5.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | -9.40% |
| Margin Operasi (TTM) | 0.99% |
| EPS Cair (TTM) | -3.69 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 48.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.49% |
| Nisbah Semasa (MRQ) | 1.96 |
| Aliran Tunai Operasi (OCF TTM) | 212.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -120.68 M |
| Pulangan Atas Aset (ROA TTM) | -3.22% |
| Pulangan Atas Ekuiti (ROE TTM) | -11.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BeOne Medicines Ltd. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 0.0 |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -4.0 |
| Purata | -0.60 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 17.31% |
| % Dimiliki oleh Institusi | 43.94% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LEE CHAN HENRY | - | 263.92 | -590 | -155,713 |
| OYLER JOHN | - | 263.92 | -3,693 | -974,657 |
| WANG LAI | - | 263.92 | -1,169 | -308,522 |
| WU XIAOBIN | - | 263.92 | -1,357 | -358,139 |
| Jumlah Keseluruhan Kuantiti Bersih | -6,809 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,797,031 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 263.92 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WANG LAI | Pegawai | 16 Jun 2026 | Jual (-) | 1,169 | 263.92 | 308,522 |
| LEE CHAN HENRY | Pegawai | 16 Jun 2026 | Jual (-) | 590 | 263.92 | 155,713 |
| OYLER JOHN | Pegawai | 16 Jun 2026 | Jual (-) | 3,693 | 263.92 | 974,657 |
| WU XIAOBIN | Pegawai | 16 Jun 2026 | Jual (-) | 1,357 | 263.92 | 358,139 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |